Biotech

  • Wellteq (CSE.WTEQ) (OTC.WTEQF) signs letter of intent (LOI) detailing the general terms of a strategic partnership agreement with Frontier Wellness Management and its operating subsidiary Apotheek Pharma Consulting (FW-APC).
  • FW-APC are focused on marketing health and wellness solutions into their unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain.
  • Under the expected terms of a formal strategic partnership agreement, FW-APC will pay an initial EUR100,000 to Wellteq which will be expended on localization, further development, and integration. It is expected that Wellteq will be paid by each customer in accordance with their Software-as-a-Service (SaaS) user pricing.
  • Working with Wellteq's sales and marketing personnel, FW-APC will immediately initiate marketing of the Wellteq application into FW-APC's existing client list.
  • Wellteq will also be tasked with sourcing and integrating third-party applications under the strategic partnership.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

WellteQ Digital Health Inc. (CSE:WTEQ) (OTC:WTEQF) (the "Company" or "Wellteq") is pleased to announce the Company has signed a letter of intent (the "LOI") detailing the general terms of a strategic partnership with Frontier Wellness Management and its operating subsidiary Apotheek Pharma Consulting (FW-APC) in the European Union.

The FW-APC team have a combined 100 years of experience focused on marketing health and wellness solutions into their unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain.

Upon execution of a Formal Strategic Partnership Agreement, FW-APC will advance EUR100,000 to Wellteq. This amount will be applied toward application localization, development, and integration. Working with Wellteq sales and marketing personnel, FW-APC will immediately initiate marketing of the Wellteq smartphone application, working with Wellteq sales and marketing personnel, into FW-APC's existing client base. FW-APC will ensure that white label solutions of Wellteq applications will be identified as "powered by Wellteq".

Wellteq will be the technology partner for any required development of the Wellteq solution and for the sourcing and integration of third-party applications / solutions. Where ancillary revenues are generated through the deployed offerings, it is expected that the parties will agree on an equitable distribution of the revenue streams between FW-APC, Wellteq and any integrated third-party solution partners.

Wellteq is initiating European distribution ahead of schedule as part of its geographical expansion plans, reinforcing the market need for globally focused digital health platforms.

"The Spanish healthcare system is more acutely focused on prevention versus treatment when compared to most jurisdictions, and Wellteq fits perfectly within that system while also bringing significant economic benefit to those enterprises adopting the platform," stated John MacPhail, CEO of Frontier Wellness.

"The pandemic has created a demand from our network of clients to improve and increase their digital presence not only for their customers but also for their employees. Wellteq provides a truly unique and universal solution to those needs," said Carles Deulofeu, Managing Director of Apotheek Pharma Consulting.

Scott Montgomery, CEO of Wellteq, said, "Working with Frontier/Apotheek provides a unique and immediate marketing, sales and revenue opportunity for Wellteq's digital health and wellness solutions and fast-tracks our entry into the European Union through a strategic partnership with an organization that has an incredibly deep relationship network already in place."

About Frontier Wellness

Frontier Wellness Management is the parent company of Apotheek Pharma Consulting, a company focused on marketing health and wellness solutions into its unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain (ranked "Healthiest Country in the World" by Bloomberg in 2019). Apotheek, based in Barcelona, is works with strategic partners to secure, develop and market innovative and potentially industry disrupting health and wellness products and technologies into its vast network. The primary services of Apotheek include technology procurement, systems analysis, software integration, operational analysis, product integration, market research, regulatory affairs, marketing, and sales management.

About WellteQ Digital Health Inc.

WellteQ Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model, Wellteq currently has two main sectors of customers: employers and insurance companies. Wellteq has secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners, like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare.

Investor Contact:

Glen Akselrod
Bristol Investor Relations
E: glen@bristolir.com
T: (905) 326-1888
Sales & Partnership Contact:

stacey@wellteq.co

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

I n the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile

Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which Breyanzi delivered deep and durable responses

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

I n the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile

Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which Breyanzi delivered deep and durable responses

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5% improved and 34.1% preserved) at Month 48 of the DAYBREAK open-label extension trial

Zeposia was well tolerated, with more than 80% of people staying on therapy through 48 months

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia

Analysis of ongoing DAYBREAK open-label extension trial of Zeposia showed that seroconversion occurred in 100% of those treated with mRNA vaccines and in a majority of those treated with non-mRNA vaccines

New analyses to be featured in late-breaking research session at the 8th European Academy of Neurology Congress in Vienna, Austria

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal

  • Anti-Cancer activity of BriaCell's lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication.
  • Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT™ HLA types, supporting BriaCell's platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.
  • The clinical data, previously reported, included rapid tumor reduction and extended survival.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce the publication of novel scientific data and clinical data (previously reported) on BriaCell's lead candidate, Bria-IMT™. The abstract of the paper was published on-line in Recent Patents on Anti-Cancer Drug Discovery a publication focused on research (where patents have been registered) in leading therapeutic areas, targets, and agents related to anti-cancer drug discovery. The publication highlights BriaCell's approach to developing novel cellular immunotherapies for cancer and the safety and efficacy of Bria-IMT™ against advanced breast cancer in a prior clinical study through a potentially unique mechanism of action. The full text of the article will be made available.

"We are thrilled to see the congruence of our scientific insights and the clinical activity of our immunotherapy in advanced breast cancer patients," stated Dr. Williams, BriaCell's President & CEO. "This paper highlights our findings of rapid tumor shrinkage in multiple anatomic locations including difficult to treat sites like the brain. We are even more excited to see the potential positive effect on survival in these patients. Having these scientific and clinical findings published in such a highly regarded journal is a significant achievement for BriaCell. The results support our approach for selecting patients most likely to benefit from our immunotherapy. This undergirds our current strategy of building a pipeline of off-the-shelf personalized immunotherapies as potentially safe and effective treatments for advanced breast cancer and other cancers," Dr. Williams added.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV

Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV –

– If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×